The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) is a homologous to the E6-associated protein C terminus-type E3 ligase frequently overexpressed in human prostate and breast cancers due to gene amplification. Previous studies suggest that WWP1 promotes cell proliferation and survival; however, the mechanism of WWP1 action is still poorly understood. Here, we showed that WWP1 upregulates and maintains erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and epithelial growth factor receptor (EGFR) in multiple cell lines. WWP1 depletion dramatically attenuates the EGFinduced ERK phosphorylation. WWP1 forms a protein complex with RING finger protein 11 (RNF11), a negative regulator of ErbB2 and EGFR. The proteinprotein interaction is through the first and third WW domains of WWP1 and the PY motif of RNF11. Although WWP1 is able to ubiquitinate RNF11 in vitro and in vivo, WWP1 neither targets RNF11 for degradation nor changes RNF11's cellular localization. Importantly, inhibition of RNF11 can rescue WWP1 siRNA-induced ErbB2 and EGFR downregulation and growth arrest. Finally, we demonstrated that RNF11 is overexpressed in a panel of prostate and breast cancer cell lines with WWP1 expression. These findings suggest that WWP1 may promote cell proliferation and survival partially through suppressing RNF11-mediated ErbB2 and EGFR downregulation.
Introduction
The WW domain containing E3 ubiquitin protein ligase 1 (WWP1/AIP5/Tiul1) belongs to the Nedd4-like homologous to the E6-associated protein C terminus (HECT)-type E3 family (Chen and Matesic, 2007) . Nedd4-like E3s can be identified by their distinctive domain structure: an HECT domain at the C terminus for the ubiquitin transfer (Verdecia et al., 2003) , a C2 domain at the N terminus for calcium-dependent phospholipid binding, and 2-4 WW domains in the middle for protein-protein interaction with PY motifs (Mosser et al., 1998) . It has been well established that the WW domains of WWP1 can directly bind to the PY motifs of their substrates, such as Smad2 (Seo et al., 2004) , Smad7 (Komuro et al., 2004) , Runx2 (Jones et al., 2006; Shen et al., 2006) and KLF5 (Chen et al., 2005) .
To date, WWP1 has been reported to target transforming growth factor-b (TGF-b) receptor 1 (TbR1) (Komuro et al., 2004) , Smad7 (Komuro et al., 2004) , Smad2 (Seo et al., 2004) , Smad4 (Moren et al., 2005) , Runx2 (Jones et al., 2006; Shen et al., 2006) , KLF2 (Zhang et al., 2004) and KLF5 (Chen et al., 2005) for ubiquitin-mediated proteolysis. Recently, WWP1 was reported to promote p53 ubiquitination and export p53 from the nucleus (Laine and Ronai, 2007) . Through ubiquitinating its substrates, WWP1 negatively regulates TGF-b signaling. In line with this, we found that WWP1 is a potential oncogene that undergoes genomic amplification and overexpression in a subset of human prostate and breast cancers (Chen et al., 2007a, b) .
Besides TbR1, the Nedd4-like E3s have been shown to regulate the degradation of multiple membrane receptors such as the Notch receptors (Qiu et al., 2000) , insulin-like growth factor 1 receptor (IGF-1R) (Vecchione et al., 2003) , vascular endothelial growth factor receptor 2 (VEGF-R2) (Murdaca et al., 2004) , chemokine (C-X-C motif) receptor 4 (CXCR4) and epithelial growth factor receptor (EGFR) (Courbard et al., 2002; Katz et al., 2002; Magnifico et al., 2003) . It is well established that the abnormal activation of the EGF receptors is a common theme in epithelial cancer (Yarden, 2001 ). Nedd4 and Itch have been demonstrated to inhibit EGFR degradation through ubiquitinating multiple adaptor proteins essential for endocytosis such as Cbls (Courbard et al., 2002; Magnifico et al., 2003) , EPS15 (Woelk et al., 2006) , Hgs (Katz et al., 2002) or Endophilin A1 (Angers et al., 2004) . However, whether WWP1 also regulates EGFRs has never been explored.
Really interesting new gene (RING) finger protein 11 (RNF11) is a small RING finger-type E3 ligase whose expression was deregulated in breast tumors Azmi and Seth, 2005) . RNF11 was proposed to enhance EGFR degradation (Azmi and Seth, 2005; Burger et al., 2006) . RNF11 has a PY motif and has been shown to be an interacting protein of the HECTtype E3s Smurf2 and Itch Subramaniam et al., 2003) . By yeast two-hybrid, RNF11 was also shown to interact with WWP1 (Azmi and Seth, 2005) . However, complete analysis of the relationship between WWP1 and RNF11 has been lacking, although both proteins were implicated in breast and prostate cancers. In this study, we provided multiple lines of evidence to support that WWP1 interacts with the RNF11 protein and inhibits RNF11-mediated erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and EGFR downregulation.
Results

WWP1 overexpression upregulates ErbB2 and EGFR
The WWP1 gene is frequently amplified and overexpressed in human prostate and breast cancers (Chen et al., 2007a, b) . Interestingly, we found that WWP1 overexpression by lentiviruses promotes MCF10A cell proliferation in an E3 ligase activity independent manner (Chen et al., 2007b) . We examined the ErbB2 and EGFR protein levels in the WWP1 overexpressed MCF10A cell populations and found that both ErbB2 H thymidine incorporation. The LacZ control was defined to be 100. **Po0.01 (t-test). W is the WT human WWP1, and Wm is the catalytic inactive human WWP1C890A. The cell populations with a low passage number (o3) were used in this study. (c) The expression levels of ErbB2 are decreased in MCF7 and HCC1500 when WWP1 is knocked down (EGFR is undetectable in these two cell lines 
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C Chen et al and EGFR are upregulated by WWP1 in a ligase activity independent manner ( Figure 1a ). Consistently, cell proliferation is significantly increased by WWP1, as determined by DNA synthesis (Figure 1b) . Similar results were obtained in MDA-MB-231 (Figures 1a  and b ). To determine whether WWP1 promotes cell proliferation partially through ErbB2 and EGFR, we treated the MCF10A-LacZ and MCF10A-WWP1 cells with ErbB2 and EGFR dual kinase inhibitor Lapatinib (5-10 mM) and examined EGFstimulated DNA synthesis. As shown in Supplementary Figure S1 , Lapatinib effectively blocks EGF-induced ERK phosphorylation and WWP1-induced but not overall cell proliferation in MCF10A.
WWP1 depletion downregulates ErbB2
We have previously shown that WWP1 siRNAs induce cell growth arrest and apoptosis in MCF7 and HCC1500 (Chen et al., 2007b Figure 2a , the cell surface staining for ErbB2 and EGFR is significantly decreased by WWP1 knockdown in MCF10A (Po0.01). The decrease of EGFR is more obvious than the decrease of ErbB2. We further performed qRT-PCR and found that the mRNA levels of ErbB2 and EGFR are not changed by WWP1 siRNA in MCF10A (Figure 2b ). These findings suggest that the regulation of ErbB2 and EGFR by WWP1 may occur at the posttranslational level.
On ligand binding, ErbB2 and EGFR will form homo-or hetero-dimmers and be autophosphorylated, which results in signaling transduction. To test whether WWP1 depletion inhibits EGF signaling, we transfected MCF10A cells with the Luc siRNA and WWP1 siRNA respectively and treated cells with 50 ng/ml EGF for different times. As reported, EGF induces rapid degradation of EGFR but not ErbB2. Consistent with previous results, WWP1 depletion decreases the levels of ErbB2 and EGFR (Figure 2c) . Importantly, the activation of ERK in response to EGF is dramatically inhibited by WWP1 siRNA in terms of strength and time (Figure 2c ).
WWP1 interacts with RNF11 in vivo and in vitro via WW/PY motifs The molecular mechanism of WWP1 upregulating ErbB2 and EGFR is unknown. A potential WWP1 interacting protein RNF11 has been reported to promote EGFR degradation (Burger et al., 2006) . RNF11 is a Cbl-like RING finger E3 ubiquitin ligase with a PY (PPXY) motif which could interact with the WW domains of WWP1. To test whether RNF11 interacts with WWP1 through the PY/WW motifs, we performed glutathione S-transferase (GST) pull-down and co-immunoprecipitation (IP) assays in HEK293 T cells. As shown in Figure 3a , a catalytic inactive form of mouse WWP1 (Myc-WWP1C886S) is specifically pulled down by GST-RNF11 but not GST or GST-RNF11Y40A (The PY motif is disrupted) (Subramaniam et al., 2003) . At the same time, GST-RNF11 but not GST-RNF11Y40A can be co-immunoprecipitated with the Myc-WWP1C886S protein in the reciprocal experiments ( Figure 3b ). In adddition, we found that RNF11-V5 prefers to bind to the first and third WW domains of WWP1 by GST pull-down assay ( Figure 3c ). Furthermore, the interaction between WWP1 and RNF11 is not affected by EGF signaling in 22Rv1 cells (Supplementary Figure S2) . These findings suggest that the WWP1 protein could interact with the RNF11 protein in cultured mammalian cells via the WW/PY motifs.
To determine if WWP1 directly interacts with RNF11 in vitro, we performed GST pull-down experiments using the purified recombinant GST-WWP1 fusion protein and the in vitro translated 35 S-labeled RNF11 protein. Both GST-WWP1 and mutant GST-WWP1C886S can pull down the RNF11 protein, but the GST protein cannot bind to the RNF11 protein under the same condition ( Figure 3d ). We found that RNF11Y40A is not associated with either GST-WWP1 or GST-WWP1C886S (data not shown). To test whether endogenous RNF11 interacts with endogenous WWP1, we immunoprecipitated endogenous RNF11 from MCF7 and found that the endogenous WWP1 protein is in the same complex (Figure 3e ).
Finally, we tested if WWP1 co-localizes with RNF11 in cells. It has been established that WWP1 localizes in the membrane, endosome, or nucleus (Martin-Serrano et al., 2005; Flasza et al., 2006) whereas RNF11 is located in the endosome (Anderson et al., 2007) in HEK293T cells. To directly visualize WWP1 under the fluorescence microscopy, we generated a construct (Myc-mCherry-WWP1) which expresses mCherry fused WWP1. The fusion of mCherry to WWP1 does not affect the protein interaction with RNF11-V5, the function of WWP1, and subcellular localization of WWP1 (Supplementary Figure S3) . We cotransfected expression plasmids for Myc-mCherry-WWP1 and RNF11-V5 into HEK293T cells and examined the subcellular localization of WWP1 and RNF11. We observed that Myc-mCherry-WWP1 is predominantly overlapping with RNF11-V5 in the endosome (Figure 3f ). These findings further suggest that WWP1 may interact with RNF11 in cultured mammalian cells.
WWP1 ubiquitinates RNF11 in vitro and in vivo
To test whether WWP1 promotes RNF11 ubiquitination, we first performed an ubiquitin conjugation assay in vitro using the recombinant GST-WWP1 protein and in vitro-translated 35 S-labeled RNF11 and RNF11Y40A. In the presence of ubiquitination reagents from an in vitro ubiquitin conjugation kit, RNF11 is not selfubiquitinated, although RNF11 is an E3 ligase. As expected, the recombinant GST-WWP1 protein significantly decreases the native wild-type (WT) RNF11 protein level and increases its ubiquitination (lane 4 in Figure 4a ). A band corresponding to monoubiquitinated RNF11 was clearly detected. Under the same conditions, mutant GST-WWP1C886S (lane 5) or GST (lane 3) has no effect on RNF11 ubiquitination in vitro. Similarly, GST-WWP1 has no effect on the mutant RNF11Y40A protein (lane 9 in Figure 4a ). These results suggest that both the ligase activity of WWP1 and protein interaction between WWP1 and RNF11 are A total of 50 ng/ml EGF was used to treat siRNA-transfected (for 48 h) and serum-starved (for overnight) MCF10A cells. The total ERK level serves as the loading control; LE, long exposure; SE, short exposure.
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C Chen et al required for RNF11 to be ubiquitinated by WWP1 in this cell-free system. To further test if WWP1 ubiquitinates the RNF11 protein in vivo, we transfected the expression construct for GST-RNF11 into HEK293T cells. We found that the RNF11 protein is heavily ubiquitinated without WWP1 in vivo (data not shown). This could be caused by RNF11 self-ubiquitination in cells because RNF11 itself is a RING finger-type E3. As mentioned above, RNF11 is not self-ubiquitinated in vitro. It is possible that the RNF11 matched ubiquitin conjugation enzyme E2 does not exist in the rabbit ubiquitin conjugation system. To avoid RNF11 self-ubiquitination in vivo, we generated a mutant RNF11 (GST-RNF11DR) in which the RING finger domain (94-154 residue) is deleted. Indeed, the ubiquitination of GST-RNF11DR is barely detected in the absence of WWP1 (Figure 4b, lane 1) . Expression of WWP1 significantly increases a smear of the RNF11 protein with higher molecular weights than WT GST-RNF11DR (lane 2), as determined by the anti-GST Ab. Notably, the ubiquitination is not polyubiquitination but likely monoubiquitination (mUb) or multi-mUb. Expression of mutant Myc-WWP1C886S does not induce ubiquitination of GST-RNF11DR (lane 3). In contrast, the original existing monoubiquitinated band disappears in the presence of WWP1C886S. These results indicate that WWP1 may induce mUb of RNF11 in vivo.
As RNF11 is an E3 ligase, we also tested whether RNF11 ubiquitinates WWP1 in vivo. The FLAG-WWP1C890A mutant was used in this experiment because WT WWP1 is self-ubiquitinated in HEK293 T cells (Supplementary Figure S4) . We observed that RNF11-V5 increases but RNF11DR-V5 (a dominant negative RNF11 mutant without the E3 ligase activity but with WWP1 interaction ability) decreases the ubiquitination of FLAG-WWP1C890A. These data suggest that RNF11 may also ubiquitinate WWP1.
WWP1 does not target RNF11 for degradation
As WWP1 is an E3 ligase for RNF11, we asked whether WWP1 targets RNF11 for ubiquitin-mediated degradation S-labeled RNF11 protein but the GST protein did not. (e) Endogenous RNF11 interacts with WWP1 in MCF7. The MCF7 cell lysate from one 100 mm dish was immunoprecipitated with either 5 ml mouse anti-RNF11 antibody (Abnova) or mouse IgG. The blot was probed with rabbit anti-WWP1 and anti-RNF11 Abs. Five percent of the input cell lysate was used as the control. (f) Co-localization of WWP1 and RNF11 in HEK293T cells. RNF11-V5 was detected by immunofluorescence staining using anti-V5 Ab. Myc-mCherry-WWP1 can be directly visualized under the fluorescent microscope. RNF11-V5 was reported to localize to the endosome in HEK293T cells (Anderson et al., 2007) .
WWP1 upregulates
by the 26S proteasome. To this end, we examined whether the endogenous RNF11 level is increased when WWP1 is knocked down. We found that the RNF11 protein levels are not elevated by WWP1 siRNAs in MCF7 (Figure 4c ), MCF10A (Figure 6a ) or PC-3 (Supplementary Figure S5) . At the same time, WWP1 overexpression does not decrease the endogenous RNF11 protein levels in MDA-MB-231 (Figure 4c ). These findings suggest that WWP1 does not regulate the RNF11 stability. Similarly, RNF11 ablation does not affect the protein levels of WWP1 in MCF10A and PC-3 (Figures 5a, 6a and Supplementary Figure S5 ).
RNF11 downregulates ErbB2 and EGFR
To test whether RNF11 downregulates ErbB2 and EGFR, we knocked down endogenous RNF11 by two different siRNAs in MCF10A. As shown in Figure 5a , both anti-RNF11 siRNAs significantly silence the RNF11 protein expression in MCF10A. As a result, RNF11 depletion significantly elevates the ErbB2 and EGFR levels compared with the negative control Luc siRNA, as determined by western blot. Similar results were obtained from MCF7, BT20 and HeLa cancer cell lines (Supplementary Figure S6) . We confirmed the upregulation of the cell surface ErbB2 and EGFR levels in MCF10A by flow cytometry (Figure 5b and Supplementary Figure S7 ). Similar to WWP1 overexpression, RNF11 siRNA 1 does not change the mRNA levels of ErbB2 or EGFR in MCF10A (Figure 5c ) and HeLa (data not shown). When RNF11 is knocked down in MCF10A, the EGF-induced pERK levels are upregulated in terms of strength and time (Figure 5d ). We noticed that RNF11 siRNA elevates the overall ErbB2 and EGFR levels but does not block EGF-induced EGFR degradation. As expected, RNF11 ablation by siRNA promotes cell proliferation as determined by DNA synthesis (Figure 5e ). Similar results were also observed in BT20 and HeLa (data not shown).
WWP1 inhibits RNF11's function RNF11 promotes but WWP1 suppresses TGF-b signaling (Subramaniam et al., 2003; Komuro et al., 2004; Li and Seth, 2004; Seo et al., 2004; Moren et al., 2005) . These reports suggest that WWP1 may inhibit RNF11's function. Interestingly, RNF11 was also reported to inhibit EGF signaling by promoting EGFR endocytosis and degradation (Azmi and Seth, 2005; Burger et al., 2006) . Indeed, we found that RNF11 siRNA increases both ErbB2 and EGFR and promotes cell proliferation in MCF10A ( Figure 5 ). In contrast, WWP1 siRNA reduces both ErbB2 and EGFR (Figure 2 ). Thus, RNF11si should be able to rescue the WWP1si induced growth arrest and ErbB2/EGFR decrease in MCF10A, if WWP1 functions through inhibiting RNF11. To this end, we transfected RNF11si and WWP1si individually and together into the MCF10A and examined ErbB2 and EGFR levels and cell proliferation by DNA synthesis. As expected, RNF11 knockdown effectively rescues the WWP1 knockdown-induced ErbB2 and EGFR decrease (Figure 6a ) and growth arrest (Figure 6b ). RNF11 knockdown also effectively rescues the WWP1 knockdown-induced ErbB2 and EGFR decrease in PC-3 (Supplementary Figure S5) . These results indicate that WWP1 upregulates ErbB2/EGFR and promotes cell proliferation through inhibiting RNF11. 35 S, and the reaction products were subjected to polyacrylamide gel electrophoresis (PAGE) and autoradiography. 'Input' is in vitro translated RNF11 (lane 1) or RNF11Y40A (lane 6) proteins, which serve as negative controls. Lanes 2 and 7 also serve as negative controls because only the ubiquitin conjugation reagents but not any GST recombinant proteins were added into the reactions. (b) Wild-type (WT) but not catalytic inactive WWP1C886S ubiquitinates GST-RNF11DR in HEK293T cells. The GST-RNF11DR proteins were pulled down by Glutathione Sepharose 4B beads and detected by anti-GST Ab. (c) WWP1 does not affect the stable levels of endogenous RNF11 in breast cancer cells. Two WWP1 siRNAs were transfected into MCF7. The target sequence of W 1 siRNA is provided in experimental procedures. The target sequence of W 2 siRNA has been shown in a previous study (Chen et al., 2007a) . Human WWP1 and WWP1C890A overexpressing MDA-MB-231 cells have been described in Figure 1 .
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C Chen et al RNF11 is overexpressed in prostate and breast cancer cell lines Although RNF11 is a negative regulator of ErbB2 and EGFR, RNF11 has been reported to be overexpressed in breast cancer as detected by immunohistochemistry (IHC) Azmi and Seth, 2005) . To confirm this result, we examined the RNF11 levels in breast cancer cell lines by qRT-PCR in 17 breast cancer 
C Chen et al cell lines and four nontransformed breast epithelial cell lines. RNF11 mRNA is upregulated at least twofold in 13 breast cancer cell lines compared with the average levels of RNF11 mRNA in four nontransformed cell lines (Figure 7a) . Similarly, we found that RNF11 mRNA is upregulated in 50% (14/28) of prostate cancer cell lines/xenografts (Figure 7b ). RNF11 overexpression in breast and prostate cancer cell lines was further confirmed at the protein level (Figures 7c and d) . Interestingly, WWP1 expression is also upregulated in these breast and prostate cancer cell lines except BT20 (Chen et al., 2007a, b) . In a panel of breast cancer cell lines, the expression levels of WWP1 appear to be associated with the ErbB2 levels (Supplementary Figure S8) .
Discussion
The WWP1 gene undergoes frequent genomic amplification at 8q21 and concomitant overexpression in human prostate and breast cancers. Functionally, forced overexpression of WWP1 promotes cell proliferation in an E3 ligase independent manner, and WWP1 knockdown significantly suppresses cancer cell proliferation and induces apoptosis. Although WWP1 is a potential oncogene in prostate and breast cancers, the molecular mechanism of WWP1 action is not very clear. In this study, we found that WWP1 overexpression upregulates ErbB2 and/or EGFR in MCF10A, MDA-MB231 and MCF7 (Figures 1 and 2 ). In addition, WWP1 knockdown downregulates ErbB2 and/or EGFR in MCF7, HCC1500, MCF10A and PC-3, suggesting that WWP1 may promote cell proliferation and survival partially through positively regulating ErbB receptors.
We provide several lines of evidence here to support that WWP1 upregulates ErbB2 and EGFR indirectly through inhibiting RNF11. First, WWP1 interacts with RNF11 through the WW/PY motifs. Second, both WWP1 overexpression and RNF11 ablation increase the ErbB2 and EGFR levels. Most importantly, RNF11 ablation can rescue the WWP1 knockdown induced ErbB2 and EGFR downregulation. The notion that WWP1 inhibits RNF11 is further supported by the facts that RNF11 promotes (Subramaniam et al., 2003; Li and Seth, 2004 ) but WWP1 suppresses TGF-b signaling (Komuro et al., 2004; Seo et al., 2004; Moren et al., 2005) . Finally, co-expression of WWP1 and RNF11 provides the opportunity for WWP1 to inhibit RNF11 in prostate and breast cancer cells. These findings suggest that WWP1 may suppress the RNF11 
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C Chen et al activity and then upregulate the ErbB2 and/or EGFR levels. Thus, WWP1 may function through RNF11 to promote EGF signaling and to inhibit TGF-b signaling. The protein interaction between WWP1 and RNF11 is supported by several lines of results. First, RNF11 was reported to be a WWP1 interacting protein by two independent yeast two-hybrid experiments (Azmi and Seth, 2005; Rual et al., 2005) . Second, we demonstrated that WWP1 interacts with RNF11 in vivo by GST pull-down assays and reciprocal co-IP experiments (Figures 3a-c) . The PY motif of RNF11 and the WW domains of WWP1 are responsible for the protein interaction. We further showed that the GST-WWP1 protein directly interacts with the RNF11 protein in vitro (Figure 3d) . Importantly, we demonstrated that endogenous WWP1 interacts with endogenous RNF11 in vivo (Figure 3e) . Finally, WWP1 and RNF11 co-localize in the endosomal system as determined by immunofluorescence staining (Figure 3f ). Taken together, the WWP1 protein interacts with the RNF11 protein through the WW/PY motifs.
The consequence of protein interaction between WWP1 and RNF11 is that both proteins can be mutually ubiquitinated (Figure 4 and Supplementary Figure S4 ). However, degradation of the WWP1 and RNF11 proteins is not affected. WWP1 upregulates both ErbB2 and EGFR in MCF10A and MDA-MB-231 in a ligase activity independent manner (Figure 1a) suggests that the ubiquitination of RNF11 may not be essential for WWP1 to upregulate ErbB2 and EGFR. Under physiological conditions, we cannot exclude that WWP1 regulates the RNF11 activity through mUb or multi-mUb because WWP1 is rarely mutated, at least in prostate cancer cells (Chen et al., 2007a) . The RNF11 protein is an ubiquitin receptor containing an ubiquitininteracting motif. Ubiquitin receptors frequently undergo mUb, which contributes to membrane receptor endocytosis and degradation (Hoeller et al., 2006) . It was proposed that the mUb of ubiquitin receptors blocks the endocytosis-signaling transduction because of intramolecular interactions between ubiquitins and their ubiquitin-binding domains (Hoeller et al., 2006) . Whether mUb of RNF11 inactivates the RNF11 activity of downregulating ErbB2 and EGFR requires further studies.
WWP1 does not change the subcellular localization of RNF11. RNF11 was shown to localize to endosomal membranes (Anderson et al., 2007) . WWP1 can also be recruited to the endosome (Plant et al., 1997; Martin-Serrano et al., 2005) . WWP1 has been reported to export p53 out of the nucleus (Laine and Ronai, 2007) . However, we found that WWP1 does not alter the RNF11 localization (Figure 3e and data not shown). Thus, a possible explanation is that the WWP1 binding may be sufficient to affect the RNF11 activity.
RNF11 has been proposed to downregulate EGFR through targeting AMSH (an EGFR deubiquitinating enzyme) for degradation by forming a complex with Smurf2 (Burger et al., 2006) . Whether the WWP1 and RNF11 complex targets AMSH for degradation needs further investigation. Several other molecules involved in EGFR endocytosis, including EPS15 and Cbl, may also be regulated by WWP1 and RNF11. EPS15 and Cbl have been demonstrated to be RNF11-interacting proteins in yeast two-hybrid experiments (Azmi and Seth, 2005) . WWP1 has been shown to increase the ubiquitination of EPS15 (Woelk et al., 2006; Chen and Matesic, 2007) . In addition, a WWP1 family member, Itch/AIP4, has been shown to promote Cbl ubiquitination (Magnifico et al., 2003) . Therefore, we cannot exclude that WWP1 also upregulates ErbB2 and EGFR through RNF11 independent mechanisms, such as EPS15 and Cbl. As RNF11 ubiquitinates WWP1, it is also possible that RNF11 inhibits the WWP1 activity. The mechanism by which RNF11 regulates ErbB2 and EGFR receptors remains to be confirmed by independent studies.
The RNF11 protein has been shown to be overexpressed in breast tumors by IHC (Subramaniam et al., 2003) . RNF11 may also be involved in Parkinson's disease (Anderson et al., 2007) . We found that WWP1 and RNF11 are concomitantly upregulated in some prostate and breast cancer cell lines (Figure 7 ). It is possible that RNF11 is neutralized by elevated WWP1 in prostate and breast cancer cell lines. The mechanism of RNF11 overexpression in cancer cells is not clear, although the WWP1 overexpression is caused by gene amplification. The expression correlation between WWP1 and ErbB2 still need to be validated in breast tumors by IHC.
In summary, we found that WWP1 upregulates both ErbB2 and EGFR receptors through inhibiting the RNF11 activity. Given the important role of ErbB2 and EGFR in cell proliferation, survival and tumorigenesis, our findings that WWP1 and RNF11 regulate the ErbB2 and EGFR levels may have a profound impact in understanding the role of WWP1 and RNF11 in the development and progression of human cancer or other diseases.
Materials and methods
Antibodies and reagents
The anti-GST (no. G7781), anti-b-actin (no. A5441), anti-FLAG and anti-V5 antibodies (Abs) were purchased from Sigma (St Louis, MO, USA). The anti-Myc, anti-PARP, antipERK and anti-ERK Abs are from Cell Signaling (Danvers, MA, USA). The anti-ErbB2 Ab, anti-HA Ab and protein A/G Plus-agarose IP reagent (sc-2003) are from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The anti-EGFR Ab, R-phycoerythrin (PE)-conjugated anti-EGFR and antiErbB2 Abs and IgG2b k isotype control are from BD Biosciences (San Jose, CA, USA). The anti-WWP1 Ab is from Novus Biologicals Inc. (Littleton, CO, USA). The rabbit anti-RNF11 Ab has been described in a previous study (Subramaniam et al., 2003) . The mouse anti-RNF11 antibody was purchased from Abnova (Taiwan). All anti-WWP1 and anti-RNF11 siRNA were purchased from Dharmacon (Lafayette, CO, USA). The target sequence for WWP1 siRNA is 5 0 -GACCAAAGCTTTCCTTGAT-3 0 . The target sequence for RNF11 siRNA 1 is 5 0 -GATGACTGGTTGATGAGAT-3 0 . The target sequence for RNF11 siRNA 2 is 5 0 -TAGGATAGCT CAAAGAATA-3 0 . EGF was purchased from Peprotech Inc.
WWP1 upregulates ErbB2 and EGFR through RNF11 C Chen et al (Rocky Hill, NJ, USA). Lapatinib was purchased from LC laboratories (Woburn, MA, USA).
Plasmid constructions
Myc-WWP1 (mouse), Myc-WWP1C886S (mouse), WWP1 (human) and WWP1C890A (human) have been described in previous studies (Chen et al., 2005 (Chen et al., , 2007b . A plasmid pRSETBmCherry, expressing a red fluorescence protein mCherry, was kindly provided by Dr Roger Y Tsien (Shaner et al., 2004) . The mCherry gene was amplified with primers mCh-F and mCh-R (all primers are listed in Supplementary Table 1) and cloned into the pCMV-Myc-WWP1 vector. The resulting construct Myc-mCherry-WWP1 was confirmed by DNA sequencing. To generate GST-RNF11DR, the cDNA encoding the first 93 amino acids of RNF11 was amplified and cloned into the pEBG vector. RNF11-V5 and RNF11DR-V5 were amplified with primers RNF11-F and RNF11-V5-R or RNF11DR-V5-R and cloned into the pLenti6/V5 vector. The WW domains 1-4 from human WWP1 were amplified by PCR using the corresponding primers listed in Supplementary  Table 1 and cloned into the pEBG vector individually.
Mutagenesis
To generate WWP1 siRNA resistant WWP1 cDNA, we silently mutated five nucleotides within the siRNA target sequence (from 5 0 -GCTTTCCTTGAT-3 0 to 5 0 -GCCTTTTTG GAC-3 0 ), using a PCR-based approach.
Cell culture and transfection
The HEK293T and MDA-MB-231 cells were maintained in DMEM media with 5% FBS and 1% penicillin and streptomycin in the incubator with 5% CO 2 . MCF10A, MCF7, HCC1500 and PC-3 cell lines were cultured as described in our previous studies (Chen et al., 2007a, b) . All plasmids and siRNAs were transfected into cells using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
Measurement of the cell surface ErbB2 and EGFR level by flow cytometry MCF10A cells were transfected with different siRNAs for 2 days. The cells were trypsinized, centrifuged and resuspended in the PBS buffer with 2% BSA (80 ml for 1 million cells). The cells were incubated with 20 ml anti-ErbB2, anti-EGFR Abs or IgG for 30 min at 4 1C. Following that, the unbound Abs were removed by centrifuge. The cells were washed once and resuspended with the PBS buffer with 2% BSA for flow cytometry.
GST pull-down and co-immunoprecipitation The GST pull-down assay and IP using the anti-Myc Ab was performed as described in our previous study (Chen et al., 2005) . For the GST pull-down assay in vitro, RNF11 and RNF11Y40A proteins were translated in vitro using the TNT Quick Coupled Transcription/Translation Systems (Promega, WI, USA) in the presence of 35 S-methinone (MP Biomedicals, OH, USA).
Ubiquitin conjugation assay
The Ubiquitin-Protein Conjugation Kit (BostonBiochem, MA, USA) was used for the in vitro ubiquitination assay as described in our previous study (Chen et al., 2005) . For the RNF11 and WWP1 ubiquitin assay in vivo, HEK293T cells were transfected with HA-Ub and other constructs as necessary. At 48 h after transfection, the cells were collected and pulled down with Glutathione Sepharose 4B beads or FLAG-M2 agarose beads under denaturing conditions. Eluted proteins were subjected to immunoblotting.
qRT-PCR Total RNA was extracted using the Trizol reagent (Invitrogen). The cDNA was prepared by using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Quantative RT-PCR was performed using the Absolute QPCR SYBR green fluorescein mixes (ABgene, Surrey, UK). Primer sequences for RNF11 are shown in Supplementary Table 1. All qPCRs were performed in duplicate. The average ratio of RNF11 to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control in normal, primary and immortalized epithelial cells was defined as 1, and the ratios for other samples were normalized accordingly. RNF11 overexpression was defined in a sample when the ratio of RNF11 to GAPDH was X2.
Abbreviations
EGFR, epithelial growth factor receptor; ErbB2, erythroblastic leukemia viral oncogene homolog 2; GST, glutathione Stransferase; HECT, homologous to the E6-associated protein C terminus; IHC, immunohistochemistry; IP, immunoprecipitation; mUb, monoubiquitination; RING, really interesting new gene; RNF11, RING finger protein 11; TGF-b, transforming growth factor-b; WT, wild type; WWP1, WW domain containing E3 ubiquitin protein ligase 1.
